Pre-made Anbenitamab benchmark antibody ( Bispecific mAb, anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-ab-023

* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry

SKU GMP-Bios-ab-023 Category Tags ,

Product Details

Pre-Made Anbenitamab biosimilar, Bispecific mAb: Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Products Name (INN Index)

Pre-Made Anbenitamab biosimilar, Bispecific mAb: Anti-ERBB2 (Domain II);ERBB2 (Domain IV) therapeutic antibody

INN Name

Anbenitamab

Target

ERBB2 (Domain II),ERBB2 (Domain IV)

Format

Bispecific/biparatopic

Derivation

Bispecific antibody

Species Reactivity

Human

CH1 Isotype

IgG1

VD LC

Kappa,Kappa

Highest_Clin_Trial (Jan '20)

Phase-II

Est. Status

Active

100% SI Structure

None;1fvc:DC:BA/4hkz:BA/1n8z:BA/6bhz:HL:IM/6bi2:HL:IM/6bi0:HL:IM/5xhg:BA:DC/6mh2:AB:CD

99% SI Structure

None;1fve:BA:DC/4x4x:AB:CD/6bgt:BA/7kbp:CC

95-98% SI Structure

None;5tdo:DC/5tdn:BA:DC/5tdp:BA:DC/4x4y:CD:AB/1fvd:BA:DC/3be1:HL/3bdy:HL/5u6a:BA/5u3d:BA/5u5f:BA/6b9z:BA/5u5m:BA/6bah:BA/4ioi:BA/4hjg:BA/6bae:BA/6b9y:BA/6dn0:AB:CD/6my4:HL:AB/6mxs:HL:AB/6my5:AB:HL/6m

Year Proposed

2020

Companies

Alphamab

Conditions Approved

NA

Conditions Active

Breast cancer,Gastric cancer

Conditions Discontinued

NA

Development Tech

NA

Previous Name

NA

Gm Offical Target Name

ERBB2 (Domain II),ERBB2 (Domain IV)

Package

, ,

Genemeidi Omicron Variant Products
test
Previous slide
Next slide